Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

374.24 +0.21 (+0.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 165,973
Open 378.49
Bid (Size) 374.00 (2)
Ask (Size) 374.67 (2)
Prev. Close 374.03
Today's Range 367.36 - 378.49
52wk Range 249.50 - 387.89
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
  
Via Benzinga

Performance

YTD
+6.60%
+6.60%
1 Month
+5.08%
+5.08%
3 Month
+24.99%
+24.99%
6 Month
+28.85%
+28.85%
1 Year
+18.68%
+18.68%

More News

Read More
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Via Benzinga
argenx: Q2 Earnings Insights
Via Benzinga
Recap: argenx Q2 Earnings
Via Benzinga
What 5 Analyst Ratings Have To Say About argenx
Via Benzinga
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
From argenx SE
Via Globe NewsWire
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via Globe NewsWire
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know
Via Benzinga
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space
Via Benzinga
Golden Cross Appears Before argenx Investors
Via Benzinga
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
Via Benzinga
Recap: argenx Q1 Earnings
Via Benzinga
Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
Via Benzinga
Recap: argenx Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Via Benzinga
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
From argenx SE
Via Business Wire
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
Via Benzinga
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
Via Benzinga
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Via Benzinga
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
What 8 Analyst Ratings Have To Say About argenx
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.